Novartis – pioneering the way forward in the treatment of NCDs
Johannesburg: In South Africa, two out of every five deaths can be attributed to non-communicable diseases (NCDs) and injuries; 40 percent of deaths among men, and 29 percent among women are premature and before the age of 60. Over 40 percent of the population suffers from high blood pressure, and over ten percent has high blood glucose, increasing the risk for diabetes.
The NCDs causing the highest number of deaths in SA are cardiovascular diseases (18%), cancer (7%), respiratory diseases (4%), diabetes (2%) and other NCDs such as asthma and cataracts (9%).
While NCDs are the leading causes of death globally, SA is still battling the HIV/AIDS and TB epidemics, which top the mortality lists. But NCDs are fast catching up and more and more South Africans are becoming ill and dying from these diseases. NCDs make up four of the top 10 causes of death in South Africa – and these numbers are on the rise, according to Statistics South Africa.
However, it’s not all doom and gloom as much progress has been made in this area. In an effort to overcome the plight of NCDs in South Africa, pharmaceutical company Novartis, has been one of the pioneers in the area of NCDs through its wide portfolio of biologic and biosimilar treatments and the company continually conducts research to discover other breakthrough medicines in this regard.
Three things that can help combat the plight of NCDs include: the reduction of underlying risk factors (tobacco use, physical inactivity, unhealthy diets, and harmful use of alcohol), early detection, and timely treatments.
It is in the last of the three, namely timely treatments, that the use of biologics and biosimilars can make such a huge difference to South Africans.
The role of biologics and biosimilar treatments
Biologics are made using human or animal proteins – a complicated and lengthy process. They do something which normal medications cannot do, namely block specific interactions in the immune system, and so are able to fight diseases in a new and effective manner.
Biologics are particularly effective in treating inflammation, auto-immune diseases, cancer, cardiovascular diseases and metabolic conditions; all of which are on the rise in South Africa.
A substantial amount of time and research goes into developing biologics and there are strict guidelines to which these medicines must adhere, making their timeframe for entry to market that much longer. However, biosimilars, which are similar to existing biological medicines, are already approved for use, and have specifically been developed to make quick and affordable access to treatments by more South Africans a reality.
Novartis was the first to develop and launch biosimilars in every major region of the world.
There are currently eleven biosimilar medicines in the pipeline from Novartis, with six more to follow in 2018.
“Sandoz, Novartis’ generic and biosimilar pharmaceutical division, has decades of experience in pharmaceutical biotechnology and is recognised as a worldwide pioneer and leader in the production of biosimilars, which are safe, effective, high quality and affordable versions of existing biological medicines,” says Dr Thomas Kowallik, CEO and Country President of Novartis SA.
Part of the SA government’s plan to combat the rising number of deaths from NCDs lies in the cost-effective management (by treatment) of high-risk individuals, and it is here that the biosimilars made available by Novartis can save a huge number of lives in SA.
Bespoke Strategic Communications
Breaking News »
So, you are thinking of having that baby…
By Marlise Kotze, Financial Planner at Alexander Forbes Retail
I just came back from maternity leave with my second child in January. I know most people will warn you about the sleepless nights, vomits ...
Read More »
| || |
Understanding supplementary medical services
By Cape Medical Plan
Supplementary services, like any medical service you receive, are often subject to an authorisation process. Although this might seem frustrating, it is implemented to protect both your ...
Read More »
| || |
Dialogue, HIV testing campaign targets men, boys
Deputy President Cyril Ramaphosa will on Thursday participate in the launch of the Religious Leaders’ Dialogue Series and HIV Testing Services Campaign in Soshanguve, north of Pretoria. The Deputy President ...
Read More »
| || |
BHF announces new Managing Director
Dr Katlego Mothudi, Managing Director
Board of Healthcare Funders of Southern Africa
Read More »